Lovaza Mechanisms of Action
Status unconfirmed · Phase 4
Conditions studied: Moderate Hypertriglyceridemia.
In brief
High levels of triglycerides is a common abnormality found in patients with diabetes and also cardiovascular disease, and may contribute to the risk for both. Omega 3 fatty acids, as found enriched in fish and also in the commercial agent called Lovaza lower triglyceride levels. Prior work from the investigators group demonstrated that an enzyme responsible for the break down of triglycerides - lipoprotein lipase - generates molecules that can activate a specific nuclear receptor known as PPAR-alpha. This study investigates the hypothesis that taking Lovaza shifts the specific fatty acid content of triglyceride containing lipoproteins and increases the ability of those lipoproteins to activate PPAR-alpha.
Key facts
- Study ID
- NCT01301794
- Run by
- Brigham and Women's Hospital
- People needed
- 40
- Starts
- 2012-08-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2013-02-25
Who can join
Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Otherwise healthy 21 to 65 year old men and women
- Triglycerides >150 < 500 mg/dL
You may not qualify if…
- Other lipid lowering medication including fish oil
- Major illnesses
- Diabetes
- Cardiovascular disease
- Abnormalities uncovered on screening blood work including undiagnosed diabetes, abnormal liver function tests, triglycerides > 500 mg/dL
- Indication for immediate statin therapy
- Pregnancy
- Contraindication for fish oil use or muscle biopsy
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.